Cargando…

Antiretroviral drugs and acute pancreatitis in HIV/AIDS patients: is there any association? A literature review

In HIV-seropositive individuals, the incidence of acute pancreatitis may achieve 40% per year, higher than the 2% found in the general population. Since 1996, when combined antiretroviral therapy, known as HAART (highly active antiretroviral therapy), was introduced, a broad spectrum of harmful fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Natalia Mejias, Ferreira, Felipe Augusto Yamauti, Yonamine, Raquel Yumi, Chehter, Ethel Zimberg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto Israelita de Ensino e Pesquisa Albert Einstein 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898250/
https://www.ncbi.nlm.nih.gov/pubmed/24728257
http://dx.doi.org/10.1590/S1679-45082014RW2561
_version_ 1782436320720715776
author Oliveira, Natalia Mejias
Ferreira, Felipe Augusto Yamauti
Yonamine, Raquel Yumi
Chehter, Ethel Zimberg
author_facet Oliveira, Natalia Mejias
Ferreira, Felipe Augusto Yamauti
Yonamine, Raquel Yumi
Chehter, Ethel Zimberg
author_sort Oliveira, Natalia Mejias
collection PubMed
description In HIV-seropositive individuals, the incidence of acute pancreatitis may achieve 40% per year, higher than the 2% found in the general population. Since 1996, when combined antiretroviral therapy, known as HAART (highly active antiretroviral therapy), was introduced, a broad spectrum of harmful factors to the pancreas, such as opportunistic infections and drugs used for chemoprophylaxis, dropped considerably. Nucleotide analogues and metabolic abnormalities, hepatic steatosis and lactic acidosis have emerged as new conditions that can affect the pancreas. To evaluate the role of antiretroviral drugs to treat HIV/AIDS in a scenario of high incidence of acute pancreatitis in this population, a systematic review was performed, including original articles, case reports and case series studies, whose targets were HIV-seropositive patients that developed acute pancreatitis after exposure to any antiretroviral drugs. This association was confirmed after exclusion of other possible etiologies and/or a recurrent episode of acute pancreatitis after re-exposure to the suspected drug. Zidovudine, efavirenz, and protease inhibitors are thought to lead to acute pancreatitis secondary to hyperlipidemia. Nucleotide reverse transcriptase inhibitors, despite being powerful inhibitors of viral replication, induce a wide spectrum of side effects, including myelotoxicity and acute pancreatitis. Didanosine, zalcitabine and stavudine have been reported as causes of acute and chronic pancreatitis. They pose a high risk with cumulative doses. Didanosine with hydroxyurea, alcohol or pentamidine are additional risk factors, leading to lethal pancreatitis, which is not a frequent event. In addition, other drugs used for prophylaxis of AIDS-related opportunistic diseases, such as sulfamethoxazole-trimethoprim and pentamidine, can produce necrotizing pancreatitis. Despite comorbidities that can lead to pancreatic involvement in the HIV/AIDS population, antiretroviral drug-induced pancreatitis should always be considered in the diagnosis of patients with abdominal pain and elevated pancreatic enzymes.
format Online
Article
Text
id pubmed-4898250
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Instituto Israelita de Ensino e Pesquisa Albert Einstein
record_format MEDLINE/PubMed
spelling pubmed-48982502016-08-10 Antiretroviral drugs and acute pancreatitis in HIV/AIDS patients: is there any association? A literature review Oliveira, Natalia Mejias Ferreira, Felipe Augusto Yamauti Yonamine, Raquel Yumi Chehter, Ethel Zimberg Einstein (Sao Paulo) Review In HIV-seropositive individuals, the incidence of acute pancreatitis may achieve 40% per year, higher than the 2% found in the general population. Since 1996, when combined antiretroviral therapy, known as HAART (highly active antiretroviral therapy), was introduced, a broad spectrum of harmful factors to the pancreas, such as opportunistic infections and drugs used for chemoprophylaxis, dropped considerably. Nucleotide analogues and metabolic abnormalities, hepatic steatosis and lactic acidosis have emerged as new conditions that can affect the pancreas. To evaluate the role of antiretroviral drugs to treat HIV/AIDS in a scenario of high incidence of acute pancreatitis in this population, a systematic review was performed, including original articles, case reports and case series studies, whose targets were HIV-seropositive patients that developed acute pancreatitis after exposure to any antiretroviral drugs. This association was confirmed after exclusion of other possible etiologies and/or a recurrent episode of acute pancreatitis after re-exposure to the suspected drug. Zidovudine, efavirenz, and protease inhibitors are thought to lead to acute pancreatitis secondary to hyperlipidemia. Nucleotide reverse transcriptase inhibitors, despite being powerful inhibitors of viral replication, induce a wide spectrum of side effects, including myelotoxicity and acute pancreatitis. Didanosine, zalcitabine and stavudine have been reported as causes of acute and chronic pancreatitis. They pose a high risk with cumulative doses. Didanosine with hydroxyurea, alcohol or pentamidine are additional risk factors, leading to lethal pancreatitis, which is not a frequent event. In addition, other drugs used for prophylaxis of AIDS-related opportunistic diseases, such as sulfamethoxazole-trimethoprim and pentamidine, can produce necrotizing pancreatitis. Despite comorbidities that can lead to pancreatic involvement in the HIV/AIDS population, antiretroviral drug-induced pancreatitis should always be considered in the diagnosis of patients with abdominal pain and elevated pancreatic enzymes. Instituto Israelita de Ensino e Pesquisa Albert Einstein 2014 /pmc/articles/PMC4898250/ /pubmed/24728257 http://dx.doi.org/10.1590/S1679-45082014RW2561 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Oliveira, Natalia Mejias
Ferreira, Felipe Augusto Yamauti
Yonamine, Raquel Yumi
Chehter, Ethel Zimberg
Antiretroviral drugs and acute pancreatitis in HIV/AIDS patients: is there any association? A literature review
title Antiretroviral drugs and acute pancreatitis in HIV/AIDS patients: is there any association? A literature review
title_full Antiretroviral drugs and acute pancreatitis in HIV/AIDS patients: is there any association? A literature review
title_fullStr Antiretroviral drugs and acute pancreatitis in HIV/AIDS patients: is there any association? A literature review
title_full_unstemmed Antiretroviral drugs and acute pancreatitis in HIV/AIDS patients: is there any association? A literature review
title_short Antiretroviral drugs and acute pancreatitis in HIV/AIDS patients: is there any association? A literature review
title_sort antiretroviral drugs and acute pancreatitis in hiv/aids patients: is there any association? a literature review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898250/
https://www.ncbi.nlm.nih.gov/pubmed/24728257
http://dx.doi.org/10.1590/S1679-45082014RW2561
work_keys_str_mv AT oliveiranataliamejias antiretroviraldrugsandacutepancreatitisinhivaidspatientsisthereanyassociationaliteraturereview
AT ferreirafelipeaugustoyamauti antiretroviraldrugsandacutepancreatitisinhivaidspatientsisthereanyassociationaliteraturereview
AT yonamineraquelyumi antiretroviraldrugsandacutepancreatitisinhivaidspatientsisthereanyassociationaliteraturereview
AT chehterethelzimberg antiretroviraldrugsandacutepancreatitisinhivaidspatientsisthereanyassociationaliteraturereview